Nanotherapeutics Hub joins forces with iiCON
The Nanotherapeutics hub and iiCON step up the UK’s infectious disease R&D pipeline.
iiCON, led by the Liverpool School of Tropical Medicine (LSTM) and backed by UKRI’s Strength in Places Fund (SIPF), has joint forces with the Nanotherapeutics Hub to support companies looking to develop nanotherapeutics to combat infectious diseases. The nanomedicine market is currently expected to be worth $169 billion USD by 2026.
The Nanotherapeutics Hub will support companies with advanced analytical capabilities and expertise in the fields of biocompatibility, biodistribution and pharmacokinetics. Furthermore, it will support with physical and chemical characterization as well as development of improved models to optimize therapeutic delivery. The consortium supports industry in bringing to market novel therapeutics and products to address the growing menace of infectious diseases and antimicrobial resistance (AMR).